AU2001233913A1 - Bcmp 84, a protein associated to breast cancer - Google Patents

Bcmp 84, a protein associated to breast cancer

Info

Publication number
AU2001233913A1
AU2001233913A1 AU2001233913A AU3391301A AU2001233913A1 AU 2001233913 A1 AU2001233913 A1 AU 2001233913A1 AU 2001233913 A AU2001233913 A AU 2001233913A AU 3391301 A AU3391301 A AU 3391301A AU 2001233913 A1 AU2001233913 A1 AU 2001233913A1
Authority
AU
Australia
Prior art keywords
breast cancer
bcmp
protein associated
prognosis
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001233913A
Other languages
English (en)
Inventor
Robert Simon Boyd
Alasdair Craig Stamps
Jonathan Alexander Terrett
Kerry Louise Tyson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0004576.5A external-priority patent/GB0004576D0/en
Priority claimed from GB0031341A external-priority patent/GB0031341D0/en
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Publication of AU2001233913A1 publication Critical patent/AU2001233913A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AU2001233913A 2000-02-25 2001-02-21 Bcmp 84, a protein associated to breast cancer Abandoned AU2001233913A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0004576 2000-02-25
GBGB0004576.5A GB0004576D0 (en) 2000-02-25 2000-02-25 Proteins
GB0031341 2000-12-21
GB0031341A GB0031341D0 (en) 2000-12-21 2000-12-21 Protein
PCT/GB2001/000729 WO2001062914A1 (en) 2000-02-25 2001-02-21 Bcmp 84, a protein associated to breast cancer

Publications (1)

Publication Number Publication Date
AU2001233913A1 true AU2001233913A1 (en) 2001-09-03

Family

ID=26243736

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2001233913A Abandoned AU2001233913A1 (en) 2000-02-25 2001-02-21 Bcmp 84, a protein associated to breast cancer
AU3392901A Pending AU3392901A (en) 2000-02-25 2001-02-21 Proteins
AU2001233929A Ceased AU2001233929C1 (en) 2000-02-25 2001-02-21 Use of breast cancer associated membrane proteins (BCMP) for treatment, prophylaxis and diagnosis of breast cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU3392901A Pending AU3392901A (en) 2000-02-25 2001-02-21 Proteins
AU2001233929A Ceased AU2001233929C1 (en) 2000-02-25 2001-02-21 Use of breast cancer associated membrane proteins (BCMP) for treatment, prophylaxis and diagnosis of breast cancer

Country Status (14)

Country Link
US (3) US20030130214A1 (enExample)
EP (2) EP1259604A1 (enExample)
JP (1) JP2003524017A (enExample)
KR (1) KR100740761B1 (enExample)
CN (1) CN100384875C (enExample)
AT (1) ATE352311T1 (enExample)
AU (3) AU2001233913A1 (enExample)
BR (1) BR0108659A (enExample)
CA (1) CA2399999A1 (enExample)
DE (1) DE60126248T2 (enExample)
ES (1) ES2279801T3 (enExample)
IL (1) IL151448A0 (enExample)
NZ (1) NZ520967A (enExample)
WO (2) WO2001062914A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7054758B2 (en) 2001-01-30 2006-05-30 Sciona Limited Computer-assisted means for assessing lifestyle risk factors
GB0125072D0 (en) * 2001-10-18 2001-12-12 Oxford Glycosciences Uk Ltd Protein
WO2003075014A2 (en) * 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
US20040033530A1 (en) * 2002-04-08 2004-02-19 Awrey Donald E. High throughput purification, characterization and identification of recombinant proteins
GB0208331D0 (en) * 2002-04-11 2002-05-22 Oxford Glycosciences Uk Ltd Proteins
FR2846426B1 (fr) * 2002-10-28 2004-12-10 Bio Merieux Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
JP2006526382A (ja) * 2002-12-06 2006-11-24 シンガポール ジェネラル ホスピタル ピーティーイー リミテッド 中枢神経系の損傷
WO2005029083A1 (en) * 2003-09-22 2005-03-31 Green Peptide Co., Ltd. Prognosis in cancer patients vaccinated with a cancer antigen peptide-associated agent
WO2005034994A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 固形腫瘍治療剤
JP2007520217A (ja) * 2004-01-27 2007-07-26 コンピュゲン ユーエスエイ，インク． 新規ヌクレオチドおよびアミノ酸配列、ならびにそれを用いた乳癌診断のためのアッセイおよび使用方法
KR100763902B1 (ko) * 2004-02-20 2007-10-05 삼성전자주식회사 유방암 특이적 단백질, 그를 코딩하는 유전자, 및 상기단백질 또는 유전자를 이용한 유방암의 진단 방법
WO2008104803A2 (en) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
KR101398079B1 (ko) * 2011-10-10 2014-05-27 재단법인 의약바이오컨버젼스연구단 글리실-티알엔에이 합성효소 및 캐드헤린을 이용한 암 예방 또는 치료제의 스크리닝 방법
CN104447975A (zh) * 2014-11-18 2015-03-25 深圳市人口和计划生育科学研究所 一种提取人肿瘤细胞膜蛋白的方法
WO2017011375A1 (en) * 2015-07-10 2017-01-19 University Of Iowa Reseaarch Foundation Bst-2 as a therapeutic target and a predictive/prognostic bio-signature for breast cancer growth and metastasis
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508652A (ja) * 1996-08-23 2002-03-19 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド 新規なヒト増殖因子
DE19813839A1 (de) * 1998-03-20 1999-09-23 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Brusttumorgewebe
NZ516381A (en) * 1999-06-30 2004-03-26 Corixa Corp Lung tumor proteins in the therapy and diagnosis of lung cancer

Also Published As

Publication number Publication date
DE60126248T2 (de) 2007-07-05
WO2001062784A2 (en) 2001-08-30
NZ520967A (en) 2004-04-30
HK1056692A1 (zh) 2004-02-27
AU2001233929B2 (en) 2005-09-08
KR20030007440A (ko) 2003-01-23
CA2399999A1 (en) 2001-08-30
CN100384875C (zh) 2008-04-30
WO2001062914A1 (en) 2001-08-30
ATE352311T1 (de) 2007-02-15
ES2279801T3 (es) 2007-09-01
AU3392901A (en) 2001-09-03
US20070212368A1 (en) 2007-09-13
EP1259604A1 (en) 2002-11-27
WO2001062784A3 (en) 2002-01-31
DE60126248D1 (de) 2007-03-15
CN1426307A (zh) 2003-06-25
AU2001233929C1 (en) 2006-03-02
BR0108659A (pt) 2002-11-05
KR100740761B1 (ko) 2007-07-19
US20030130214A1 (en) 2003-07-10
EP1257285A2 (en) 2002-11-20
US20030099662A1 (en) 2003-05-29
IL151448A0 (en) 2003-04-10
EP1257285B1 (en) 2007-01-24
JP2003524017A (ja) 2003-08-12

Similar Documents

Publication Publication Date Title
WO2003087831A3 (en) Proteins involved in breast cancer
AU2001233913A1 (en) Bcmp 84, a protein associated to breast cancer
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
MXPA05014166A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
AU2002245317A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
AU5624699A (en) Use of 5ht-6 antagonists
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
MXPA03003151A (es) Metodos de diagnostico de cancer de prostata, composiciones y metodos para seleccionar moduladores de cancer de prostata.
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
BG105270A (en) Tetrahydropyridoethers
AU2002249871A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
GB0031527D0 (en) New use
AU3752700A (en) Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
BG105197A (en) Polymorph form of a medicament
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
AU2002348297A1 (en) Proteonomic methods for diagnosis and monitoring of breast cancer
AU2001243349A1 (en) Methods for the diagnosis and treatment of breast cancer
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
AU2001233917A1 (en) Bcmp-7 as marker for diagnosis of breast cancer
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
TR200200278T2 (tr) Kalsilitik bileşimler
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.